[Efficacy and safety of hydromorphone hydrochloride extended-release tablets in patients with moderate-to-severe chronic cancer pain: a multicenter, double-blind, non-inferiority randomized controlled trial].
Once-daily hydromorphone extended-release works as well as twice-daily oxycodone for cancer pain, simplifying medication schedules for patients.
This PubMed record examines [Efficacy and safety of hydromorphone hydrochloride extended-release tablets in patients with moderate-to-severe chronic cancer pain: a multicenter, double-blind, non-inferiority randomized controlled trial]. It reports Conclusion: Once-daily hydromorphone ER was non-inferior to twice-daily oxycodone CR for managing moderate-to-severe chronic cancer pain, with similar safety profiles and no statistically significant difference in satisfaction scores, providing an effective therapeutic option with a simplified dosing regimen.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants
- Category
- Other
- Maturity
- Validated
- Journal
- Zhonghua yi xue za zhi
Why it surfaced
Randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.